Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
Niagen Bioscience, Inc. (
NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the publication of independent preclinical research in Nature Communications led by a team at Sichuan Agricultural University identifying the CD38 enzyme as a primary driver of NAD+ decline in aging tissue, and that nicotinamide riboside (NR) restored NAD+ and improved placental, fetal, and offspring outcomes in aged mice despite elevated CD38.
Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
Niagen Bioscience, Inc. (
NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the Midwest IDEAS Investor Conference on Thursday, August 27, 2026, at The InterContinental Chicago in Chicago, IL.
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
Niagen Bioscience, Inc. (
NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026.
Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External ResearchNiagen Bioscience, Inc. (
NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the appointment of Abhijit Kale, Ph.D., as Senior Director of Global External Research, effective July 20, 2026.
Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen
Niagen Bioscience, Inc. (
NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces it is the headlining sponsor of the inaugural NAD for Health: Opportunities & Challenges scientific meeting hosted by the University of Copenhagen, taking place March 23–25, 2026 at the Royal Danish Academy of Sciences and Letters in central Copenhagen. Space is limited and registration is required; see registration details at the end of this release.
